Share your experience validating the SARS-CoV-2 IgG Antibody assay1

Thank you for taking the time to provide feedback on the first semi-quantitative SARS-CoV-2 antibody assay to be granted Emergency Use Authorization by the FDA. We are interested in learning as much as possible about the experience of laboratorians who validate this assay.

Participants who complete the questionnaire below can receive 50% off their first ordered kit of SARS-CoV-2 IgG assay reagent and consumables. Once you have completed the survey, a Siemens Healthineers representative will be in touch with you with confirmation of your eligibility for this offer.

Did you compare your validation study of Siemens Healthineers SARS-CoV-2 IgG assay against another vendor's SARS-CoV-2 antibody assay?

Is your lab actively performing patient testing with a SARS-CoV-2 antibody assay?

How confident are you in the accuracy of your current SARS-CoV-2 antibody assay, on a scale of 1 through 5? (1: not confident, 5: highly confident)

During your validation study and comparison, did you notice any significant difference between the results produced by SH COV2G and your current antibody assay?

Are you aware of the advantages that targeting the S1 RBD protein can have for producing accurate and actionable test results?

Are you interested in further discussing your experience using the SARS-CoV-2 IgG semi-quantitative assay with a Siemens Healthineers clinical representative?